研究表明Sarclisa和Blenrep大大改善了多位骨髓瘤患者的治疗结果。 Studies show Sarclisa and Blenrep significantly improve outcomes for multiple myeloma patients.
新的研究表明,如果将Sarclisa药物与新诊断的多细胞瘤的标准治疗相结合,将带来重大的好处,改善无进展生存,并导致采取更深入和更持久的对策。 New studies show significant benefits of the drug Sarclisa when combined with standard treatments for newly diagnosed multiple myeloma, improving progression-free survival and leading to deeper and more durable responses. 在目前的治疗方案之外添加该药物,导致最低残留疾病(MRD)的消极性发病率较高,而没有新的安全考虑。 The drug's addition to current regimens resulted in higher rates of minimal residual disease (MRD) negativity without new safety concerns. 同时,GSK的Blenrep在与其他药物一起使用时,将复发多重骨髓瘤患者的死亡风险降低了42%,有可能将预期寿命延长近3年。 Meanwhile, GSK's Blenrep, when used with other drugs, reduced the risk of death by 42% in patients with relapsed multiple myeloma, potentially extending life expectancy by nearly three years.